Drug Trial Radar · NCT04318743
A Bridging Trial to Compare the PK Profile When Glepaglutide is Administered Via Vial/Syringe Versus Autoinjector.
Last checked: Nov 20, 2026Latest source record: Jul 14, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
85
Actual
Start
Mar 4, 2020
Primary completion
Jun 10, 2021
Study completion Jun 10, 2021
Sponsor
- Lead sponsor
- Zealand PharmaIndustry
- Sponsor type
- Industry
- First posted
- Mar 24, 2020
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Crossover
- Masking
- None
- Primary purpose
- Other
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 54 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This is an open-label, randomized, single center, 2-treatment, 3-period, 3-sequence reference-replicated, crossover trial in healthy subjects to compare the PK of glepaglutide (ZP1848) after a single SC administration by vial/syringe and by autoinjector.
Conditions
- Healthy
Interventions
GlepaglutideDrug
GLP-2
Primary outcomes
What the sponsor says the trial is designed to measure.
- Pharmacokinetic VariablesTime frame: From time zero to the last time point with a measurable concentration
- Pharmacokinetic VariablesTime frame: from time zero to the last time point with a measurable concentration
Locations
1 site in 1 country. Site status is shown where the registry gives one.
PRA Health Sciences- Location Martini
Groningen, NZ, Netherlands
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.